Your browser doesn't support javascript.
loading
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Varga, Andrea; Piha-Paul, Sarina; Ott, Patrick A; Mehnert, Janice M; Berton-Rigaud, Dominique; Morosky, Anne; Yang, Ping; Ruman, Jane; Matei, Daniela.
Afiliação
  • Varga A; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Andrea.VARGA@gustaveroussy.fr.
  • Piha-Paul S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ott PA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mehnert JM; Developmental Therapeutics/Phase I Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Berton-Rigaud D; Service de Cancérologie médicale, ICO Centre René Gauducheau, Saint-Herblain, France.
  • Morosky A; Department of Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Yang P; Biostatistics and Research Decision Sciences, MSD China, Beijing, China.
  • Ruman J; Department of Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Matei D; Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Gynecol Oncol ; 152(2): 243-250, 2019 02.
Article em En | MEDLINE | ID: mdl-30522700

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Antígeno B7-H1 / Carcinoma Epitelial do Ovário Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Antígeno B7-H1 / Carcinoma Epitelial do Ovário Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2019 Tipo de documento: Article